Aarkstore - Fatty Liver Disease-Pipeline Insights, 2014

1
Fatty Liver Disease-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/healthcare/77058/-fatty-l
  iver-disease-pipeline-insights-2014

2
Summary

• DelveInsights, Fatty Liver Disease-Pipeline
  Insights, 2014, report provides comprehensive
  insights about pipeline drugs across this
  indication. A key objective of the report is to
  establish the understanding for all the pipeline
  drugs that fall under Fatty Liver Disease. This
  report provides information on the therapeutic
  development based on the Fatty Liver Disease
  dealing with all the pipeline drugs, comparative
  analysis at various stages covering Filed, Phase
  III, Phase II, Phase I, IND filed, Preclinical,
  Discovery and unknown stages, therapeutics
  assessment by monotherapy and combination
  products and molecule type drug information. The
  report also covers the companies information
  involved in the therapeutic development of the
  products. It also has highlighted the
  discontinued and dormant products.

3
Summary

• Data Sources
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.Secondary
  sources information and data has been collected
  from various printable and non-printable sources
  like search engines, News websites, Government
  Websites, Trade Journals, White papers,
  Magazines, Trade associations, Books, Industry
  Portals, Industry Associations and access to
  available databases.Note This report requires
  certain updates. We have all the information
  available but require 3 business days to complete
  the process and ensure it is as up-to-date as
  possible. Certain sections in the report may be
  removed or altered based on the availability and
  relevance of data for the indicated Indication.

4
Summary

• Scope 
• The report provides a snapshot of the global
  therapeutic landscape of Fatty Liver DiseaseThe
  report provides pipeline products under drug
  profile section which includes product
  description, MOA, licensors collaborators,
  development partner and chemical
  informationCoverage of the Fatty Liver Disease
  pipeline on the basis of target, MOA, route of
  administration, technology involved and molecule
  typeThe report reviews key players involved in
  the therapeutics development for Fatty Liver
  Disease and also provide company profilingThe
  report also gives the information of dormant and
  discontinued pipeline projects Pipeline products
  coverage based on various stages of development
  ranging from preregistration till discovery and
  undisclosed stages Provides pipeline assessment
  by monotherapy and combination therapy products,
  stage of development and molecule type

5
Summary

• Reasons to buyComplete Pipeline intelligence
  and complete understanding over therapeutics
  development for Fatty Liver DiseaseIdentify the
  relationship between the drugs and use it for
  target finding, drug repurposing, and precision
  medicine.Devise corrective measures for pipeline
  projects by understanding Fatty Liver Disease
  pipeline depth and focus of Indication
  therapeutics Developing strategic initiatives to
  support your drug development activities.Optimize
  your portfolio and keep you in touch with the
  rapidly changing pharmaceutical markets, and make
  the best decisions for your business.

6
Summary

• Develop and design in licensing and out licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and ScopeProvides
  strategically significant competitor information,
  analysis, and insights to formulate effective RD
  development strategies Modify the therapeutic
  portfolio by identifying discontinued projects
  and understanding the factors that drove them
  from pipelineGaining a Full Picture of the
  Competitive Landscape for Evidence based Decisions

7
Table of Content

• Fatty Liver Disease OverviewFatty Liver Disease
  Pipeline TherapeuticsFatty Liver Disease
  Therapeutics under Development by
  Companies Fatty Liver Disease Late Stage
  Products (Filed and Phase III)Comparative
  Analysis Fatty Liver Disease Mid Clinical Stage
  Products (Phase II)Comparative Analysis Fatty
  Liver Disease Early Clinical Stage Products
  (Phase I and IND Filed)Comparative
  Analysis Fatty Liver Disease Discovery and
  Pre-Clinical Stage Products Comparative
  Analysis Drug Candidate Profiles

8
Table of Content

• Fatty Liver Disease Therapeutics
  Assessment Assessment by Monotherapy
  Products Assessment by Combination
  Products Assessment by Route of
  Administration Assessment by Molecule
  Type Fatty Liver Disease Discontinued
  Products Fatty Liver Disease Dormant
  ProductsCompanies Involved in Therapeutics
  Development for Fatty Liver Disease Appendix Met
  hodology Contact Us Disclaimer

9
List of Tables

• Number of Products under Development for Fatty
  Liver Disease, 2014Number of Products under
  Development by Companies Comparative Analysis by
  Late Clinical Stage Products (Filed and Phase
  III), 2014Comparative Analysis Mid Clinical
  Stage Products (Phase II), 2014Comparative
  Analysis Early Clinical Stage Products (Phase I
  and IND Filed), 2014Comparative Analysis
  Discovery and Pre-Clinical Stage Products,
  2014Drug Candidates Profiles

10
List of Tables

• Fatty Liver Disease Assessment by Monotherapy
  Products Fatty Liver Disease Assessment by
  Combination Products Fatty Liver Disease
  Assessment by Route of Administration Fatty
  Liver Disease Assessment by Stage and Route of
  Administration Fatty Liver Disease Assessment by
  Molecule Type Fatty Liver Disease Assessment by
  Stage and Molecule Type Fatty Liver Disease
  Therapeutics Discontinued Products Fatty Liver
  Disease Therapeutics Dormant ProductsProducts
  under Development by Companies, 2014

11
List of Figures

• Number of Products under Development for Fatty
  Liver Disease, 2014Late Clinical Stage Products
  (Filed and Phase III), 2014Mid Clinical Stage
  Products (Phase II), 2014Early Clinical Stage
  Products (Phase I and IND Filed), 2014Discovery
  and Pre-Clinical Stage Products, 2014Fatty Liver
  Disease Assessment by Monotherapy Products Fatty
  Liver Disease Assessment by Combination
  Products Fatty Liver Disease Assessment by Route
  of Administration Fatty Liver Disease Assessment
  by Stage and Route of Administration Fatty Liver
  Disease Assessment by Molecule Type Fatty Liver
  Disease Assessment by Stage and Molecule Type

12
Related Reports

• The Mobile Healthcare (mHealth) Bible 2014 -
  2020
• Pregnancy Detection Kit Market in the US
  2015-2019
• Global Prenatal and Newborn Genetic Testing
  Market 2015-2019
• Global Knee Implant market 2015-2019
• Global Isosorbide Market 2015-2019
• Ascension Health - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Accretive Health, Inc. (ACHI) - Strategic SWOT
  Analysis Review
• Jazz Pharmaceuticals plc (JAZZ) - Financial and
  Strategic SWOT Analysis Review
• Pharmstandard (PHST) - Financial and Strategic
  SWOT Analysis Review
• GLG Life Tech Corporation (GLG) - Financial and
  Strategic SWOT Analysis Review

13

• Fatty Liver Disease-Pipeline Insights, 2014
• Published Dec. 2014 60 Pages
• DelveInsights, Fatty Liver Disease-Pipeline
  Insights, 2014, report provides comprehensive
  insights about pipeline drugs across this
  indication.
  Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news